Home › Companies › 4D Molecular Therapeutics, Inc. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and 4D Molecular Therapeutics, Inc.’s Form 8-K, filed June 20, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 17, 2025: 5 items on 4D Molecular Therapeutics, Inc.’s Form 8-K, filed June 20, 2025: 2 approved · 3 passed (calculated).
Notable dissent: 2 directors (15.4%, 11.4% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Ra Capital Management, L.P. (13F, 9.7%, as of September 30, 2026)
Explore 4D Molecular Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are 4D Molecular Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 20, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jacob Chacko, M.D., MBA | 28,579,453 | -- | -- | 3,691,962 | 6,199,121 | 89% | Passed (calculated) | — |
| Elect Director: Susannah Gray, MBA | 31,923,027 | -- | -- | 348,388 | 6,199,121 | 99% | Passed (calculated) | — |
| Elect Director: Charles P. Theuer, M.D., Ph.D. | 27,285,806 | -- | -- | 4,985,609 | 6,199,121 | 85% | Passed (calculated) | — |
| 2. The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025 | 38,380,552 | 81,490 | 8,494 | -- | -- | 99.8% | Approved | — |
| 3. On an advisory, non-binding basis, the named executive officers' compensation as disclosed in the Proxy Statement | 31,841,967 | 394,002 | 35,446 | -- | 6,199,121 | 99% | Approved | — |
Source: 4D Molecular Therapeutics, Inc., Form 8-K, filed with the SEC on June 20, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
145 asset managers disclosed a vote on at least one 4D Molecular Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of 4D Molecular Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 2 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Charles Theuer, M.D., Ph.D.
4D Molecular Therapeutics, Inc.’s own tally for this item (“Elect Director: Charles P. Theuer, M.D., Ph.D.”): 27,285,806 for, 4,985,609 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 44 asset managers below reported 8,401,540 for, 343,583 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,715,854 | 0 | 0 | 0 | For |
| BlackRock | 2,349,074 | 0 | 0 | 0 | For |
| Federated Hermes | 1,526,562 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 844,378 | 0 | 0 | 0 | For |
| Charles Schwab | 284,860 | 0 | 0 | 0 | For |
| Equitable | 82,223 | 0 | 0 | 55,870 | Mixed |
| MERIDIAN FUND INC | 130,435 | 0 | 0 | 0 | For |
| TIAA | 122,085 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 86,536 | 0 | 0 | 0 | For |
| State Street | 67,402 | 0 | 0 | 13 | For |
| American Century | 0 | 0 | 0 | 44,910 | Withhold |
| Invesco | 0 | 0 | 0 | 38,706 | Withhold |
| Lincoln Financial | 31,700 | 0 | 0 | 4,816 | Mixed |
| Harbor ETF Trust | 30,595 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 28,311 | Withhold |
| Global X | 26,680 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 26,096 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 23,001 | Withhold |
| Brighthouse | 0 | 0 | 0 | 22,699 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 19,056 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 0 | 18,719 | Withhold |
| T. Rowe Price | 18,225 | 0 | 0 | 0 | For |
| Pacific Life | 17,285 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 0 | 0 | 0 | 16,350 | Withhold |
| Voya | 0 | 0 | 0 | 14,500 | Withhold |
Showing the 25 largest of 44 asset managers. All 44 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Jacob Chacko, M.D., MBA
4D Molecular Therapeutics, Inc.’s own tally for this item (“Elect Director: Jacob Chacko, M.D., MBA”): 28,579,453 for, 3,691,962 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 44 asset managers below reported 8,466,342 for, 278,781 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,715,854 | 0 | 0 | 0 | For |
| BlackRock | 2,349,074 | 0 | 0 | 0 | For |
| Federated Hermes | 1,526,562 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 844,378 | 0 | 0 | 0 | For |
| Charles Schwab | 284,860 | 0 | 0 | 0 | For |
| Equitable | 82,223 | 0 | 0 | 55,870 | Mixed |
| MERIDIAN FUND INC | 130,435 | 0 | 0 | 0 | For |
| TIAA | 122,085 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 86,536 | 0 | 0 | 0 | For |
| State Street | 67,402 | 0 | 0 | 13 | For |
| American Century | 0 | 0 | 0 | 44,910 | Withhold |
| Invesco | 38,706 | 0 | 0 | 0 | For |
| Lincoln Financial | 31,700 | 0 | 0 | 4,816 | Mixed |
| Harbor ETF Trust | 30,595 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 28,311 | Withhold |
| Global X | 26,680 | 0 | 0 | 0 | For |
| Northern Trust | 26,096 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 23,001 | Withhold |
| Brighthouse | 0 | 0 | 0 | 22,699 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 19,056 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 0 | 18,719 | Withhold |
| T. Rowe Price | 18,225 | 0 | 0 | 0 | For |
| Pacific Life | 17,285 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 0 | 0 | 0 | 16,350 | Withhold |
| Voya | 0 | 0 | 0 | 14,500 | Withhold |
Showing the 25 largest of 44 asset managers. All 44 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Susannah Gray, MBA
4D Molecular Therapeutics, Inc.’s own tally for this item (“Elect Director: Susannah Gray, MBA”): 31,923,027 for, 348,388 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 44 asset managers below reported 8,673,884 for, 71,239 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,715,854 | 0 | 0 | 0 | For |
| BlackRock | 2,349,074 | 0 | 0 | 0 | For |
| Federated Hermes | 1,526,562 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 844,378 | 0 | 0 | 0 | For |
| Charles Schwab | 284,860 | 0 | 0 | 0 | For |
| Equitable | 82,223 | 0 | 0 | 55,870 | Mixed |
| MERIDIAN FUND INC | 130,435 | 0 | 0 | 0 | For |
| TIAA | 122,085 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 86,536 | 0 | 0 | 0 | For |
| State Street | 67,415 | 0 | 0 | 0 | For |
| American Century | 44,910 | 0 | 0 | 0 | For |
| Invesco | 38,706 | 0 | 0 | 0 | For |
| Lincoln Financial | 31,700 | 0 | 0 | 4,816 | Mixed |
| Harbor ETF Trust | 30,595 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 28,311 | 0 | 0 | 0 | For |
| Global X | 26,680 | 0 | 0 | 0 | For |
| Northern Trust | 26,096 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 23,001 | 0 | 0 | 0 | For |
| Brighthouse | 22,699 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 19,056 | 0 | 0 | 0 | For |
| John Hancock | 18,719 | 0 | 0 | 0 | For |
| T. Rowe Price | 18,225 | 0 | 0 | 0 | For |
| Pacific Life | 17,285 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 16,350 | 0 | 0 | 0 | For |
| Voya | 14,500 | 0 | 0 | 0 | For |
Showing the 25 largest of 44 asset managers. All 44 are in the interactive database (link above).
Combines 10 wordings of this item as funds reported it.
99% Approved · of votes cast
Description as filed by funds: Approval, on an advisory, non-binding basis, of the compensation of the Company's named executive officers ("say-on-pay vote").
4D Molecular Therapeutics, Inc.’s own tally for this item (“3. On an advisory, non-binding basis, the named executive officers' compensation as disclosed in the Proxy Statement”): 31,841,967 for, 394,002 against — passed, per its Form 8-K filed June 20, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory, non-binding basis, the named executive officers' compensation as disclosed in the Proxy Statement.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,715,854 | 0 | 0 | 0 | For |
| BlackRock | 2,349,074 | 0 | 0 | 0 | For |
| Federated Hermes | 1,526,562 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 844,378 | 0 | 0 | 0 | For |
| Charles Schwab | 284,860 | 0 | 0 | 0 | For |
| Equitable | 138,093 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 130,435 | 0 | 0 | 0 | For |
| TIAA | 122,085 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 86,536 | 0 | 0 | 0 | For |
| State Street | 67,415 | 0 | 0 | 0 | For |
| American Century | 0 | 44,910 | 0 | 0 | Against |
| Invesco | 38,706 | 0 | 0 | 0 | For |
| Lincoln Financial | 36,516 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 30,595 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 28,311 | 0 | 0 | 0 | For |
| Global X | 26,680 | 0 | 0 | 0 | For |
| Northern Trust | 26,096 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 23,001 | 0 | 0 | 0 | For |
| Brighthouse | 22,699 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 19,056 | 0 | 0 | 0 | For |
| John Hancock | 18,719 | 0 | 0 | 0 | For |
| T. Rowe Price | 18,225 | 0 | 0 | 0 | For |
| Pacific Life | 17,285 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 16,350 | 0 | 0 | 0 | For |
| Voya | 14,500 | 0 | 0 | 0 | For |
Fund voting reports, all 44 managers: 8,700,213 for, 44,910 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BVF INC/IL | 4,585,983 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 4,399,945 | 0 | 0 | 0 | For |
| Goldman Sachs | 2,149,697 | 0 | 0 | 0 | For |
| Novo Holdings A/S | 2,000,000 | 0 | 0 | 0 | For |
| BlackRock | 1,628,797 | 0 | 0 | 0 | For |
| Janus Henderson | 1,624,391 | 0 | 0 | 0 | For |
| Federated Hermes | 1,613,728 | 0 | 0 | 0 | For |
| Two Sigma | 881,831 | 0 | 0 | 0 | For |
| State Street | 777,896 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 605,342 | 0 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 442,072 | 0 | 0 | 0 | For |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 412,000 | 0 | 0 | 0 | For |
| Northern Trust | 316,692 | 0 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 300,000 | 0 | 0 | 0 | For |
| Charles Schwab | 284,860 | 0 | 0 | 0 | For |
| JPMorgan | 271,407 | 0 | 0 | 0 | For |
| Decheng Capital LLC | 0 | 0 | 0 | 0 | -- |
| Wellington | 180,078 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 175,561 | 0 | 0 | 0 | For |
| Nuveen | 150,314 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 141,178 | 0 | 0 | 0 | For |
| Citadel | 135,868 | 0 | 0 | 0 | For |
| Invesco | 116,880 | 0 | 0 | 0 | For |
| Fidelity | 92,746 | 0 | 0 | 0 | For |
| Point72 | 67,796 | 0 | 0 | 0 | For |
Institutional-manager reports, all 113 managers: 24,082,377 for, 62,845 against, 96 not voted, 250,000 unknown, 18,353 1 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99% Fund and manager reports combined; may count the same shares twice · no official result
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Federated Hermes | 0 | 0 | 0 | 0 | -- |
| JANUS INVESTMENT FUND | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| MERIDIAN FUND INC | 0 | 0 | 0 | 0 | -- |
| TIAA | 0 | 0 | 0 | 0 | -- |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| American Century | 0 | 0 | 0 | 0 | -- |
| Invesco | 0 | 0 | 0 | 0 | -- |
| Lincoln Financial | 0 | 0 | 0 | 0 | -- |
| Harbor ETF Trust | 0 | 0 | 0 | 0 | -- |
| ALPS ETF Trust | 0 | 0 | 0 | 0 | -- |
| Global X | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| AIG/SunAmerica | 0 | 0 | 0 | 0 | -- |
| Brighthouse | 0 | 0 | 0 | 0 | -- |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 0 | 0 | -- |
| John Hancock | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| Pacific Life | 0 | 0 | 0 | 0 | -- |
| ETFis Series Trust I | 0 | 0 | 0 | 0 | -- |
| Voya | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 44 managers: 8,734,636 1 year, 10,487 3 year. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BVF INC/IL | 0 | 0 | 0 | 0 | -- |
| RA CAPITAL MANAGEMENT, L.P. | 0 | 0 | 0 | 0 | -- |
| Goldman Sachs | 0 | 0 | 0 | 0 | -- |
| Novo Holdings A/S | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Janus Henderson | 0 | 0 | 0 | 0 | -- |
| Federated Hermes | 0 | 0 | 0 | 0 | -- |
| Two Sigma | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| MARSHALL WACE, LLP | 0 | 0 | 0 | 0 | -- |
| ArrowMark Colorado Holdings LLC | 0 | 0 | 0 | 0 | -- |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| ARMISTICE CAPITAL, LLC | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | Not Voted |
| Wellington | 0 | 0 | 0 | 0 | -- |
| MELLON INVESTMENTS Corp | 0 | 0 | 0 | 0 | -- |
| Nuveen | 0 | 0 | 0 | 0 | -- |
| Redmile Group, LLC | 0 | 0 | 0 | 0 | -- |
| Citadel | 0 | 0 | 0 | 0 | -- |
| Invesco | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Point72 | 0 | 0 | 0 | 0 | -- |
| Maryland State Retirement & Pension System | 0 | 0 | 0 | 0 | -- |
| Asset Management One Co., Ltd. | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 109 managers: 21,162 for, 303 against, 96 not voted, 23,829,214 1 year, 33,737 3 year. Showing the 25 largest; every one is in the interactive database (link above).
99.8% Approved · of votes cast
Prior year: 100.0% for (May 21, 2024 meeting) ▼ 0.2 pts
Description as filed by funds: Ratification of the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.
4D Molecular Therapeutics, Inc.’s own tally for this item (“2. The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025”): 38,380,552 for, 81,490 against — passed, per its Form 8-K filed June 20, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 44 asset managers below reported 8,743,871 for, 1,252 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,715,854 | 0 | 0 | 0 | For |
| BlackRock | 2,349,074 | 0 | 0 | 0 | For |
| Federated Hermes | 1,526,562 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 844,378 | 0 | 0 | 0 | For |
| Charles Schwab | 284,860 | 0 | 0 | 0 | For |
| Equitable | 138,093 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 130,435 | 0 | 0 | 0 | For |
| TIAA | 122,085 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 86,536 | 0 | 0 | 0 | For |
| State Street | 67,414 | 1 | 0 | 0 | For |
| American Century | 44,910 | 0 | 0 | 0 | For |
| Invesco | 38,706 | 0 | 0 | 0 | For |
| Lincoln Financial | 36,516 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 30,595 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 28,311 | 0 | 0 | 0 | For |
| Global X | 26,680 | 0 | 0 | 0 | For |
| Northern Trust | 26,096 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 23,001 | 0 | 0 | 0 | For |
| Brighthouse | 22,699 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 19,056 | 0 | 0 | 0 | For |
| John Hancock | 18,719 | 0 | 0 | 0 | For |
| T. Rowe Price | 18,225 | 0 | 0 | 0 | For |
| Pacific Life | 17,285 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 16,350 | 0 | 0 | 0 | For |
| Voya | 14,500 | 0 | 0 | 0 | For |
Showing the 25 largest of 44 asset managers. All 44 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 49,778,127 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.46% |
| 2 | BlackRock | 4.72% |
| 3 | Federated Hermes | 3.07% |
| 4 | JANUS INVESTMENT FUND | 1.70% |
| 5 | Charles Schwab | 0.57% |
| 6 | Equitable | 0.28% |
| 7 | MERIDIAN FUND INC | 0.26% |
| 8 | TIAA | 0.25% |
| 9 | QUANTITATIVE MASTER SERIES LLC | 0.17% |
| 10 | State Street | 0.14% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BVF INC/IL | 9.21% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 8.84% |
| 3 | Goldman Sachs | 4.32% |
| 4 | Novo Holdings A/S | 4.02% |
| 5 | BlackRock | 3.27% |
| 6 | Janus Henderson | 3.26% |
| 7 | Federated Hermes | 3.24% |
| 8 | Two Sigma | 1.77% |
| 9 | State Street | 1.56% |
| 10 | MARSHALL WACE, LLP | 1.22% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BVF PARTNERS L P/IL | 5,346,519 | 10.74% | Schedule 13G, filed May 15, 2026 |
| JANUS HENDERSON GROUP PLC | 5,247,151 | 10.54% | Schedule 13G, filed April 7, 2026 |
| RA Capital Management, L.P. | 4,564,867 | 9.17% | Proxy statement (DEF 14A), proxy filed April 29, 2025 |
| BlackRock | 4,547,152 | 9.13% | Form 13F, quarter ended March 31, 2025 |
| Goldman Sachs | 4,168,394 | 8.37% | Form 13F, quarter ended March 31, 2025 |
| Novo Holdings A/S | 3,650,737 | 7.33% | Schedule 13G, filed February 17, 2026 |
| Vanguard Group | 2,757,490 | 5.54% | Form 13F, quarter ended March 31, 2025 |
| Biotechnology Value Fund, L.P. | 2,670,642 | 5.37% | Proxy statement (DEF 14A), proxy filed April 29, 2025 |
| Morgan Stanley | 1,776,743 | 3.57% | Form 13F, quarter ended March 31, 2025 |
| David Kirn, M.D. | 1,659,153 | 3.33% | Proxy statement (DEF 14A), proxy filed April 29, 2025 |
Percentages above are of 49,778,127 shares outstanding, as reported by 4D Molecular Therapeutics, Inc. on its Form 10-K dated February 23, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At 4D Molecular Therapeutics, Inc.'s shareholder meeting held June 17, 2025, in the 2024-2025 proxy season, 145 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,033 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on an advisory, non-binding basis, of the compensation of the Company's named… — 4D Molecular Therapeutics, Inc.'s filing reports the proposal as approved, with 99% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: 4D Molecular Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 20, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from 4D Molecular Therapeutics, Inc.’s 10-K dated February 23, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
4D Molecular Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “4D Molecular Therapeutics (FDMT) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/4d-molecular-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.